410 results on '"Kufe, Donald W."'
Search Results
2. MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer
3. Supplementary Figure 1 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
4. Supplementary Figure 3 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
5. Data from Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro
6. Data Supplement from Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro
7. Supplementary Figure 5 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
8. Supplementary Figures 1-3 from CBP501-Calmodulin Binding Contributes to Sensitizing Tumor Cells to Cisplatin and Bleomycin
9. Supplementary Figure 8 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
10. Data from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
11. Supplementary Materials and Methods and Supplementary Figure Legends from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
12. Supplementary Figure 2 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
13. Manganese Superoxide Dismutase (SOD2) Inhibits Radiation-Induced Apoptosis by Stabilization of the Mitochondrial Membrane
14. Supplementary Data from Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
15. Data from Inhibition of Nuclear Factor-κB Activity by Temozolomide Involves O6-Methylguanine–Induced Inhibition of p65 DNA Binding
16. Supplementary Figure Legends 1-10 from Inhibition of Nuclear Factor-κB Activity by Temozolomide Involves O6-Methylguanine–Induced Inhibition of p65 DNA Binding
17. Supplementary Figures 1-10 from Inhibition of Nuclear Factor-κB Activity by Temozolomide Involves O6-Methylguanine–Induced Inhibition of p65 DNA Binding
18. Abstract A032: MUC1-C regulates chromatin remodeling and drives the CSC state in human cancers
19. Emergence of MUC1 in Mammals for Adaptation of Barrier Epithelia
20. Chronic activation of MUC1-C in wound repair promotes progression to cancer stem cells
21. MUC1-Induced Alterations in a Lipid Metabolic Gene Network Predict Response of Human Breast Cancers to Tamoxifen Treatment
22. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity
23. Clinical Applications of CA 15–3
24. Membrane-Derived Second Messenger Regulates X-Ray-Mediated Tumor Necrosis Factor α Gene Induction
25. Ionizing Radiation Regulates Expression of the c-jun Protooncogene
26. Increased Tumor Necrosis Factor α mRNA after Cellular Exposure to Ionizing Radiation
27. A Broadly Neutralizing Monoclonal Antibody that Recognizes the V 3 Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp120
28. Ionizing Radiation Activates Transcription of the EGR1 Gene Via CArG Elements
29. Reactive Oxygen Intermediates Target CC(A/T) 6 GG Sequences to Mediate Activation of the Early Growth Response 1 Transcription Factor Gene by Ionizing Radiation
30. The Role of Intracellular Calcium in the Cellular Response to Ionizing Radiation
31. Ionizing Radiation Down-Regulates Histone H1 Gene Expression by Transcriptional and Post-Transcriptional Mechanisms
32. Mucins in cancer: function, prognosis and therapy
33. Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinoma
34. Antitumor effects of fusions composed of dendritic cells and fibroblasts transfected with genomic DNA from tumor cells
35. Angiostatin potentiates cyclophosphamide treatment of metastatic disease
36. Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies
37. A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion
38. Abstract 491: Encapsulation of the stem cell inhibitor Salinomycin in novel QUATRAMER sustained injectable suspension (HSB-1216) for the treatment of small cell lung cancer
39. MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment
40. Immunosuppressive milieu of high-risk localized prostate cancer.
41. Clinical Studies with Tumour Necrosis Factor
42. Pro-apoptotic effect of the c-Abl tyrosine kinase in the cellular response to 1-β-D-arabinofuranosylcytosine
43. Targeting of the MUC1-C Oncoprotein in Colitis-Associated Colorectal Cancer
44. Combined effects of angiostatin and ionizing radiation in antitumour therapy
45. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors
46. Cyclocreatine in cancer chemotherapy
47. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma
48. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents
49. Membrane-derived second messenger regulates x-ray-mediated tumor necrosis factor alpha gene induction
50. Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.